An observational study in Myotonic Dystrophy 1 and Myotonic Dystrophy 2, sponsored by Lupin Ltd.. Not yet recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Lupin Ltd. · Observational
This natural history observational study is being conducted to follow patients with DM1 or DM2 over a 2 year period to study the presence of myotonia, how it's perceived and its impact on patients quality of life. This study will be conducted at 6 study sites located in France.100 Patients will be recruited from the DM Scope Registry only. The study involves two parts. Part 1 will look back up to 18 months of past medical history that is already available from the DM Scope Registry. Part 2 will follow the same patients for 24 months, with study visits at Day 1 (Baseline), 12 months and 24 months. The goal is to better understand how myotonia symptoms and complications such as heart and other systemic problems develop and change over time. A smaller, sub-study will take place at one site, using new exploratory methods in about 40 patients with DM1 who are also part of the Track DM Study.
The rationale of the study is to gather longitudinal data on patients with DM1 and DM2 in order to better understand disease progression and evolution of myotonia and other symptoms and their associated complications/risks, particularly in relation to cardiac and other systemic manifestations. The primary objective is to investigate the evolution of myotonia presence, perception and its impact on the burden of disease over time in patients with Myotonic dystrophy type 1 (DM1) and type 2 (DM2). The secondary objective is to evaluate the progression of other DM-related multisystemic symptom manifestation such as cardiac, pulmonary, gastrointestinal (GI), hepatic, and renal impairments/disorders, muscle weakness, stumbling and falls in DM patients over 24-months. Additionally, the study will assess the use of pharmacological and non-pharmacological treatments for myotonia during the data collection period.
All of the patients will be recruited through the DM-Scope Registry. The registry database will be the source of the retrospective data to be used in the study. The study will begin with a detailed retrospective medical history assessment (up to -18 months to baseline) based on the annual routine DM-scope visits in the database. This will provide a comprehensive view of the patients' health status before the study. The 24-month prospective assessment period visits will occur at baseline, 12 months and 24 months. This approach allows for detailed tracking of disease progression and associated complications/risks over time.
The exploratory sub-study aims to broaden the understanding of DM1 pathophysiology by incorporating biophysical, functional, and behavioral measurements beyond traditional motor function and muscle strength. It also aims to evaluate the reliability of several innovative assessments, including advanced tools to deliver a multidimensional view of disease progression.
125 studies on the registry are indexed under Myotonic Dystrophy; 51 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Browse Myotonic Dystrophy studies →Lupin Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients will be recruited from DM-Scope Registry
Exclusion Criteria:
Approximately 40 patients with DM1 who are enrolled in the Track DM core study will also participate in the substudy. These patients will undergo all visits and assessments as outlined in the core study Schedule of Assessments. In addition, patients participating in the substudy will also complete exploratory assessments at Baseline, Day 14, Month 6, Month 12 and Month 24 visits. All additional exploratory assessments will be conducted at a single site and will include a set of innovative measures designed to provide an integrative, multi-dimensional view of disease progression. These assessments will complement conventional clinical evaluations by incorporating emerging and innovative biomarkers.
90 Patients with Myotonic Dystrophy Type 1 (DM1) will be enrolled in the study and data for this group will be analyzed separately
10 Patients with Myotonic Dystrophy Type 2 (DM2) will be enrolled in the study and data for this group will be analyzed separately.
Change in stiffness severity assessed by Visual Analog Scale (VAS)
Absolute change in VAS stiffness score (0-100mm) between Baseline and Month 12
Time frame: Baseline to Month 24
Change in myotonia severity assessed by the Myotonia Behavior Scale (MBS)
Absolute change in MBS score (1-6) between Baseline and Month 24.
Time frame: Baseline to Month 24
Change in disease-related activity and participation assessed by DM1-Activ
Absolute change in DM1-Activ score (0-100) between Baseline and Month 24.
Time frame: Baseline to Month 24
Change in health-related quality of life assessed by the Individualized Neuromuscular Quality of Life Questionnaire (INQoL)
Absolute change in INQoL: symptom subscores, life-domain subscores, overall total score, and treatment impact score (0-4 Likert) between Baseline and Month 24.
Time frame: Baseline to Month 24
Change in walking performance assessed by the 10-Meter Walk Test (10mWT)
Absolute change in 10mWT (sec) performance between Baseline and Month 24.
Time frame: Baseline to Month 24
Change in mobility and functional performance assessed by the Timed Up and Go Test (TUG)
Absolute change in TUG performance (sec) between Baseline and Month 24.
Time frame: Baseline to Month 24
Change in cardiac function
Assessment of cardiac manifestations of DM1 using ECG and echocardiography, including LVEF, heart rate, PR interval, QRS interval, QT interval (QTcB and QTcF), and classification of cardiac function status (Normal, Abnormal-Not Clinically Significant, Abnormal-Clinically Significant).
Time frame: Baseline and all scheduled study timepoints, including retrospective assessments up to 18 months before enrollment.
Progression of opthalmologic manifestations
Presence or absence of cataracts at each study timepoint
Time frame: Scheduled study timepoints, including retrospective assessments up to 18 months before enrollment.
Change in respiratory function
Absolute change in respiratory function as measured by spirometry, including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC ratio.
Time frame: Baseline and all scheduled study timepoints, including retrospective data up to 18 months.
Change in Physical Examination Findings
Assessment and absolute changes in physical examination parameters, including BMI (weight (kg)/Height (m2)) and other clinically relevant findings (CS/NCS) at each study timepoint.
Time frame: Baseline and all scheduled study timepoints.
Safety and Tolerability
Evaluation of adverse events, clinical laboratory parameters (hematology and biochemistry) and concomitant medication use.
Time frame: Throughout study participation.
Change in Gastrointestinal (GI) manifestations
Assessment of gastrointestinal and related symptoms using a specific questionnaire used in DM-scope, including age of onset, coughing while eating or drinking (response options: never or \<2 times/month, \>2 times/month, \>1 time/week, not investigated), feeling of food blockage, digestive difficulties (Yes/No, if yes, specify: constipation, diarrhea, alternating diarrhea-constipation), fecal incontinence, urinary incontinence, gastroesophageal reflux
Time frame: Baseline and all scheduled study timepoints, including retrospective assessments up to 18 months before enrollment.
Change in muscle-related manifestations
Assessment of disease-related muscular symptoms including dysphagia, muscle pain assessed by VAS (0-100mm), hand-opening time after contraction (sec), and swallowing function assessed by the Timed Water Swallowing Test (sec).
Time frame: Baseline and all scheduled study timepoints.
Change in mobility and functional performance
Assessment of mobility and physical function, including number of accidental falls, 10-Meter Walk Test (10mWT), and Timed Up and Go Test (TUG).
Time frame: Baseline and all scheduled study timepoints
Change in Quality of Life
Assessment of health-related quality of life using the Individualized Neuromuscular Quality of Life Questionnaire (INQoL), including symptom subscales, life-domain subscales, total score, and treatment impact score.
Time frame: Baseline and all scheduled study timepoints.
Clinical Global Impression of disease severity and change
Assessment of disease severity using the Clinical Global Impression (CGI) scale (7-point scale from normal, not at all ill, to amongst the most extremely ill) at each study timepoint.
Time frame: Baseline and all scheduled study timepoints
Exploratory Sub-study - Change in Motor Function Measures (MFM-32)
Assessment of muscle weakness and functional limitations over time using MFM-32 Scale (score 0-96)
Time frame: Baseline and all scheduled study timepoints.
Exploratory Sub-Study - Video Hand Opening Test (vHOT)
Assessment of delayed hand opening using the standardized Video Hand Opening Test. Myotonia is quantified as the time required for hand opening following voluntary contraction. Unit of Measurement: Seconds
Time frame: Baseline and all scheduled study timepoints.
Exploratory Sub Study - QMA-Based Myotonia Assessment
Detailed characterization of grip myotonia using Quantitative Muscle Assessment (QMA). Participants perform three series of six maximal grip contractions every 15 seconds, with a 10-minute rest between series. Myotonia is quantified as the average relaxation time from the first trial of each series. Unit of Measurement: seconds
Time frame: Baseline and all scheduled study timepoints
Exploratory Sub-Study - Myotone Device Myotonia Assessment
Assessment of delayed muscle relaxation using the MyoTone handheld device. The device applies a brief mechanical impulse and records muscle oscillation response to quantify stiffness and relaxation properties. Unit of measure N/m.
Time frame: Baseline and all scheduled study timepoints
Exploratory Substudy- Quadriceps Myotonia
Assessment of Myotonia using MyoTone test during knee extension to possibly detect myotonia in other muscle territories. Unit of measurement: seconds.
Time frame: Baseline and all scheduled timepoints.
Exploratory Sub-study: Muscle Imaging
Assessment of muscle fatty degenerative changes, muscle volume changes and active muscle damage by MRI. Unit of Measure: imaging derived values
Time frame: All scheduled timepoints
Exploratory Sub Study - Shear Wave Elastography (SWE) of vastus lateralis and forearm flexor compartment
Assess change in the mechanisms of myotonia at rest and during grip contractions using SWE ultrasound imaging technique. Unit of Measurement: kilopascals (kPa)
Time frame: Baseline and all scheduled timepoints
Exploratory Sub Study - Bioelectrical Impedance analysis (BIA) of the Thigh.
Change in thigh composition measured by BIA. Unit of measurement: ohms or impedance index
Time frame: Baseline and all scheduled study timepoints
Exploratory Sub Study - 30 second sit to stand test
Change in number of sit to stand repetitions completed in 30 seconds.
Time frame: Baseline and all scheduled study timepoints
Ankle Dorsiflexion Strength
Change in ankle dorsiflexion force measured by MyoAnkle dynamometry
Time frame: Baseline and all scheduled study timepoints
Swallowing Sound and Vibration Analysis
Change in swallowing acoustics and vibration patterns. Unit of Measure: device acoustic/vibration units
Time frame: Baseline and all scheduled study timepoints
Exploratory Sub Study - Home monitoring of physical activity using a wearable actimetry device
Assessment of changes in daily physical activity captured by wearable device.
Time frame: Baseline and all scheduled study timepoints
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupin Ltd.